Consequently, we hypothesized that simvastatin could protect against hyperoxia-induced bronchopulmonary dysplasia by suppressing NLRP3 activation and acting as an anti-inflammatory and antioxidant agent by upregulating KLF2 expression. The gene discussed is NLRP3; the disease is bronchopulmonary dysplasia.